Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain

PHASE2CompletedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

June 25, 2023

Study Completion Date

June 25, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain

The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).

Trial Locations (1)

Unknown

Gleneagles Hospital HongKong, Hong Kong

All Listed Sponsors
lead

Sinovac Biotech (Hong Kong) Limited

INDUSTRY